股本结构
单位：万股
| 公告日期 | 2021-11-09 | 2021-11-09 | 2021-08-09 | 2021-08-09 | 2021-05-06 | 2021-05-06 |
|---|---|---|---|---|---|---|
| 证券总股本 | 7788.89 | 7783.47 | 7773.42 | 7760.16 | 7690.01 | 7658.39 |
| 普通股本 | 7788.89 | 7783.47 | 7773.42 | 7760.16 | 7690.01 | 7658.39 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2021-11-04 | 2021-09-30 | 2021-08-02 | 2021-06-30 | 2021-04-30 | 2021-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2021-11-09 | 7788.89 | 未披露 | 定期报告 | 2021-11-04 |
| 2021-11-09 | 7783.47 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Exercises of common stock options
Vesting of restricted stock units
Shares withheld to cover taxes upon restricted stock unit vesting
|
2021-09-30 |
| 2021-08-09 | 7773.42 | 未披露 | 定期报告 | 2021-08-02 |
| 2021-08-09 | 7760.16 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
Vesting of restricted stock units
Shares withheld to cover taxes upon restricted stock unit vesting
|
2021-06-30 |
| 2021-05-06 | 7690.01 | 未披露 | 定期报告 | 2021-04-30 |
| 2021-04-20 | 7661.50 | 未披露 | 定期报告 | 2021-04-06 |
| 2021-04-20 | 7660.51 | 未披露 | 定期报告 | 2021-04-01 |
| 2021-05-06 | 7658.39 | 未披露 |
更多>>
From January 1, 2021 to March 31, 2021
Exercises of common stock options
Vesting of restricted stock units
Shares withheld to cover taxes upon restricted stock unit vesting
|
2021-03-31 |
| 2021-02-26 | 7632.09 | 未披露 | 定期报告 | 2021-02-22 |
| 2021-02-26 | 7575.72 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
Proceeds from issuance of common stock, net of commissions and offering costs of $904
|
2020-12-31 |
| 2020-11-05 | 7504.49 | 未披露 | 定期报告 | 2020-11-02 |
| 2020-11-05 | 7468.10 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Exercises of common stock options
|
2020-09-30 |
| 2020-08-06 | 7445.90 | 未披露 | 定期报告 | 2020-07-31 |
| 2020-08-06 | 7432.13 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
|
2020-06-30 |
| 2020-05-07 | 7391.64 | 未披露 | 定期报告 | 2020-04-30 |
| 2020-04-22 | 7384.28 | 未披露 | 定期报告 | 2020-04-16 |
| 2020-05-07 | 7377.91 | 未披露 |
更多>>
From January 1, 2020 to March 31, 2020
Exercises of common stock options
Proceeds from issuance of common stock, net of commissions and offering costs of$904
|
2020-03-31 |
| 2020-02-28 | 7375.06 | 未披露 | 定期报告 | 2020-02-24 |
| 2020-02-28 | 7157.32 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
Issuance of common stock to collaboration partners
|
2019-12-31 |
| 2019-11-07 | 6843.10 | 未披露 | 定期报告 | 2019-11-04 |
| 2019-08-08 | 6836.01 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
|
2019-06-30 |
| 2019-04-29 | 6832.40 | 未披露 | 定期报告 | 2019-04-22 |
| 2019-05-10 | 6828.89 | 未披露 |
更多>>
from January 1, 2019 to March 31, 2019
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
|
2019-03-31 |
| 2019-03-13 | 6826.49 | 未披露 | 定期报告 | 2019-03-04 |
| 2019-03-13 | 6821.07 | 未披露 |
更多>>
From December 31, 2017 to December 31, 2018
Proceeds from issuance of common stock from public offering, net of underwriters' commissions and offering costs of $330
Issuance of common stock to Alnylam Pharmaceuticals, Inc.
Issuance of common stock to collaboration partners
Exercise of warrants to purchase common stock
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
Vesting of restricted common stock
Settlement of restricted stock for tax withholding
|
2018-12-31 |
| 2018-11-05 | 6273.19 | 未披露 | 定期报告 | 2018-11-02 |
| 2018-11-05 | 6188.92 | 未披露 |
更多>>
From December 31, 2017 to September 30, 2018
Proceeds from issuance of common stock from public offering, net of underwriting fees and issuance costs
Issuance of common stock to Alnylam Pharmaceuticals, Inc.
Exercise of common stock options
Sale of common stock related to Employee Stock Purchase Plan
Exercise of warrants to common stock
Settlement of restricted stock for stock withholding
|
2018-09-30 |
| 2018-08-08 | 5294.97 | 未披露 | 定期报告 | 2018-08-06 |
| 2018-08-08 | 5286.78 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-14 | 5282.16 | 未披露 | 定期报告 | 2018-05-11 |
| 2018-04-26 | 5179.70 | 未披露 | 定期报告 | 2018-04-23 |
| 2018-05-14 | 5178.14 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-08 | 5176.70 | 未披露 | 定期报告 | 2018-03-07 |
| 2018-03-08 | 5164.48 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of redeemable convertible preferred stock, net of issuance costs of $750
Dividends declared, redeemable convertible preferred stock
Conversion of redeemable convertible preferred stock
Issuance of common stock from public offering, net of underwriting fees and issuance costs of $3,221
Vesting of restricted common stock
Exercise of common stock options
Sale of common stock related to employee stock purchase plan
|
2017-12-31 |
| 2017-12-29 | 5164.17 | 未披露 | 定期报告 | 2017-12-29 |
| 2017-11-02 | 2084.85 | 未披露 | 定期报告 | 2017-11-01 |
| 2017-11-02 | 2084.78 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-10 | 2084.44 | 未披露 | 定期报告 | 2017-08-09 |
| 2017-08-10 | 2079.44 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-03-30 | 2079.42 | 未披露 | 定期报告 | 2017-03-29 |
| 2017-03-30 | 2075.30 | 未披露 |
更多>>
From December 31, 2015 to September 30, 2016
Vesting of restricted common stock
Exercise of common stock options
Sale of common stock related to employee stock purchase plan
|
2016-09-30 |
| 2016-08-04 | 2075.30 | 未披露 | 定期报告 | 2016-08-02 |
| 2016-05-09 | 2072.61 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-10 | 2064.80 | 未披露 | 定期报告 | 2016-03-09 |
| 2016-03-10 | 2059.46 | 未披露 |
更多>>
From December 31, 2014 to December 31, 2015
Issuance of Common Stock from public offering, net of underwriting fees and issuance costs of $445
Vesting of restricted common stock
Exercise of common stock options
Sale of common stock related to employee stock purchase plan
|
2015-12-31 |
| 2015-11-10 | 2059.31 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-08-06 | 2059.31 | 未披露 | 定期报告 | 2015-08-05 |
| 2015-08-06 | 2058.04 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-05-11 | 1782.68 | 未披露 | 定期报告 | 2015-05-08 |
| 2015-05-11 | 1782.21 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-12 | 1782.10 | 未披露 | 定期报告 | 2015-03-11 |
| 2015-03-12 | 1778.69 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Conversion of preferred stock to common stock
Issuance of Common Stock from initial public offering, net of underwriting fees and issuance costs of $10,751
Net exercise of common stock warrant
Vesting of restricted common stock
Exercise of common stock options
Sale of common stock related to employee stock purchase plan
|
2014-12-31 |
| 2014-11-06 | 1777.33 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-08-07 | 1776.88 | 未披露 | 定期报告 | 2014-08-05 |
| 2014-08-07 | 1776.31 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-13 | 1776.31 | 未披露 | 定期报告 | 2014-05-09 |
| 2014-04-30 | 1776.14 | 未披露 | 定期报告 | 2014-04-25 |
| 2014-05-13 | 1776.11 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-01-30 | 1662.77 | 未披露 |
更多>>
The conversion of each share of Series A, Series B and Series C preferred stock into one share of common stock immediately prior to the completion of this offering has occurred.
|
2014-01-30 |
| 2014-03-27 | 3.82 | 1058.94 |
更多>>
from December 31, 2012 to December 31, 2013
Issuance of Series C preferred stock, net of issuance costs of $220
Issuance of Series C preferred stock, in redemption of bridge loan
Vesting of restricted common stock
Exercise of common stock options
|
2013-12-31 |
| 2013-12-31 | 2.81 | 1058.94 |
更多>>
from December 31, 2012 to September 30, 2013
Issuance of Series C preferred stock, net of issuance costs of $220
Issuance of Series C preferred stock, in redemption of bridge loan
Vesting of restricted common stock
Exercise of common stock options
|
2013-09-30 |
From June 30, 2021 to September 30, 2021
Exercises of common stock options
Vesting of restricted stock units
Shares withheld to cover taxes upon restricted stock unit vesting
From March 31, 2021 to June 30, 2021
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
Vesting of restricted stock units
Shares withheld to cover taxes upon restricted stock unit vesting
From January 1, 2021 to March 31, 2021
Exercises of common stock options
Vesting of restricted stock units
Shares withheld to cover taxes upon restricted stock unit vesting
From December 31, 2019 to December 31, 2020
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
Proceeds from issuance of common stock, net of commissions and offering costs of $904
From June 30, 2020 to September 30, 2020
Exercises of common stock options
From March 31, 2020 to June 30, 2020
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
From January 1, 2020 to March 31, 2020
Exercises of common stock options
Proceeds from issuance of common stock, net of commissions and offering costs of$904
From December 31, 2018 to December 31, 2019
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
Issuance of common stock to collaboration partners
From March 31, 2019 to June 30, 2019
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
from January 1, 2019 to March 31, 2019
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
From December 31, 2017 to December 31, 2018
Proceeds from issuance of common stock from public offering, net of underwriters' commissions and offering costs of $330
Issuance of common stock to Alnylam Pharmaceuticals, Inc.
Issuance of common stock to collaboration partners
Exercise of warrants to purchase common stock
Exercises of common stock options and sales of common stock under Employee Stock Purchase Plan
Vesting of restricted common stock
Settlement of restricted stock for tax withholding
From December 31, 2017 to September 30, 2018
Proceeds from issuance of common stock from public offering, net of underwriting fees and issuance costs
Issuance of common stock to Alnylam Pharmaceuticals, Inc.
Exercise of common stock options
Sale of common stock related to Employee Stock Purchase Plan
Exercise of warrants to common stock
Settlement of restricted stock for stock withholding
from December 31, 2016 to December 31, 2017
Issuance of redeemable convertible preferred stock, net of issuance costs of $750
Dividends declared, redeemable convertible preferred stock
Conversion of redeemable convertible preferred stock
Issuance of common stock from public offering, net of underwriting fees and issuance costs of $3,221
Vesting of restricted common stock
Exercise of common stock options
Sale of common stock related to employee stock purchase plan
From December 31, 2015 to September 30, 2016
Vesting of restricted common stock
Exercise of common stock options
Sale of common stock related to employee stock purchase plan
From December 31, 2014 to December 31, 2015
Issuance of Common Stock from public offering, net of underwriting fees and issuance costs of $445
Vesting of restricted common stock
Exercise of common stock options
Sale of common stock related to employee stock purchase plan
from December 31, 2013 to December 31, 2014
Conversion of preferred stock to common stock
Issuance of Common Stock from initial public offering, net of underwriting fees and issuance costs of $10,751
Net exercise of common stock warrant
Vesting of restricted common stock
Exercise of common stock options
Sale of common stock related to employee stock purchase plan
The conversion of each share of Series A, Series B and Series C preferred stock into one share of common stock immediately prior to the completion of this offering has occurred.
from December 31, 2012 to December 31, 2013
Issuance of Series C preferred stock, net of issuance costs of $220
Issuance of Series C preferred stock, in redemption of bridge loan
Vesting of restricted common stock
Exercise of common stock options
from December 31, 2012 to September 30, 2013
Issuance of Series C preferred stock, net of issuance costs of $220
Issuance of Series C preferred stock, in redemption of bridge loan
Vesting of restricted common stock
Exercise of common stock options